JP5343267B2 - タラロゾール代謝物 - Google Patents
タラロゾール代謝物 Download PDFInfo
- Publication number
- JP5343267B2 JP5343267B2 JP2009533511A JP2009533511A JP5343267B2 JP 5343267 B2 JP5343267 B2 JP 5343267B2 JP 2009533511 A JP2009533511 A JP 2009533511A JP 2009533511 A JP2009533511 A JP 2009533511A JP 5343267 B2 JP5343267 B2 JP 5343267B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- taralozole
- formula
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SNFYYXUGUBUECJ-UHFFFAOYSA-N N-{4-[2-ethyl-1-(1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol-2-amine Chemical class C=1C=C(NC=2SC3=CC=CC=C3N=2)C=CC=1C(C(CC)CC)N1C=NC=N1 SNFYYXUGUBUECJ-UHFFFAOYSA-N 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000003780 keratinization Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 229940097043 glucuronic acid Drugs 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 2
- 208000025309 Hair disease Diseases 0.000 claims 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims 1
- 208000026721 nail disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 abstract description 43
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 abstract description 3
- 229940097042 glucuronate Drugs 0.000 abstract description 2
- 229910004727 OSO3H Inorganic materials 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 17
- 210000003608 fece Anatomy 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 229950009878 talarozole Drugs 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- -1 metasulfonates Chemical class 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000005353 IP-10 production Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012440 retinoic acid metabolism blocking agent Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SNFYYXUGUBUECJ-HXUWFJFHSA-N (R)-talarozole Chemical compound N1([C@@H](C=2C=CC(NC=3SC4=CC=CC=C4N=3)=CC=2)C(CC)CC)C=NC=N1 SNFYYXUGUBUECJ-HXUWFJFHSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000029443 keratinization disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85198906P | 2006-10-17 | 2006-10-17 | |
| US60/851,989 | 2006-10-17 | ||
| PCT/US2007/081685 WO2008049027A1 (en) | 2006-10-17 | 2007-10-17 | Talarazole metabolites |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010506953A JP2010506953A (ja) | 2010-03-04 |
| JP2010506953A5 JP2010506953A5 (enExample) | 2010-09-16 |
| JP5343267B2 true JP5343267B2 (ja) | 2013-11-13 |
Family
ID=39314359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533511A Expired - Fee Related JP5343267B2 (ja) | 2006-10-17 | 2007-10-17 | タラロゾール代謝物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8188124B2 (enExample) |
| EP (1) | EP2114895A4 (enExample) |
| JP (1) | JP5343267B2 (enExample) |
| KR (1) | KR101419965B1 (enExample) |
| CN (1) | CN101611016B (enExample) |
| AU (1) | AU2007311026B2 (enExample) |
| BR (1) | BRPI0718310A2 (enExample) |
| CA (1) | CA2667053C (enExample) |
| MX (1) | MX2009004096A (enExample) |
| WO (1) | WO2008049027A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| JP5769965B2 (ja) | 2007-07-31 | 2015-08-26 | ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． | ヒト胚性幹細胞の分化 |
| CN101878298B (zh) | 2007-11-27 | 2017-08-15 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
| KR101597731B1 (ko) | 2008-02-21 | 2016-02-26 | 센토코 오르토 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
| AU2009267137A1 (en) | 2008-06-30 | 2010-01-07 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
| KR102025158B1 (ko) | 2008-10-31 | 2019-09-25 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화 |
| PL2366022T3 (pl) | 2008-11-20 | 2016-11-30 | Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych | |
| JP2012509085A (ja) | 2008-11-20 | 2012-04-19 | ヤンセン バイオテツク，インコーポレーテツド | マイクロキャリア上での多能性幹細胞の培養 |
| AU2010276438B2 (en) | 2009-07-20 | 2015-06-11 | Janssen Biotech Inc. | Differentiation of human embryonic stem cells |
| EP4410991A3 (en) | 2009-12-23 | 2024-10-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| KR20130025375A (ko) | 2010-03-01 | 2013-03-11 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포로부터 유래된 세포의 정제 방법 |
| WO2011143299A2 (en) | 2010-05-12 | 2011-11-17 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
| WO2012030538A2 (en) | 2010-08-31 | 2012-03-08 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| PH12013500389A1 (en) | 2010-08-31 | 2013-04-22 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| PH12013500349A1 (en) | 2010-08-31 | 2022-03-30 | Janssen Biotech Inc | Differentiation of pluripotent stem cells |
| US9248120B2 (en) | 2011-08-23 | 2016-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Reversing intestinal inflammation by inhibiting retinoic acid metabolism |
| JP6441080B2 (ja) | 2011-12-22 | 2018-12-19 | ヤンセン バイオテツク，インコーポレーテツド | 単一ホルモンのインスリン陽性細胞へのヒト胚性幹細胞の分化 |
| JP6383292B2 (ja) | 2012-03-07 | 2018-08-29 | ヤンセン バイオテツク，インコーポレーテツド | 多能性幹細胞の増殖及び維持のための明確な培地 |
| MX358590B (es) | 2012-06-08 | 2018-08-24 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas. |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| JP6557147B2 (ja) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化 |
| EP2938722B1 (en) | 2012-12-31 | 2021-12-08 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
| SG10201709338RA (en) | 2012-12-31 | 2017-12-28 | Janssen Biotech Inc | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| CN117821369A (zh) | 2014-05-16 | 2024-04-05 | 詹森生物科技公司 | 小分子增强胰腺内分泌细胞中的mafa表达的用途 |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100365312B1 (ko) * | 1996-06-27 | 2003-03-06 | 얀센 파마슈티카 엔.브이. | N-[4-(헤테로아릴메틸)페닐]헤테로아릴아민 |
| AP869A (en) * | 1998-01-05 | 2000-09-04 | Pfizer | 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents. |
| MXPA04005864A (es) * | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
| US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| PL372356A1 (pl) * | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
-
2007
- 2007-10-17 EP EP07854136A patent/EP2114895A4/en not_active Withdrawn
- 2007-10-17 BR BRPI0718310-0A patent/BRPI0718310A2/pt not_active IP Right Cessation
- 2007-10-17 AU AU2007311026A patent/AU2007311026B2/en not_active Ceased
- 2007-10-17 WO PCT/US2007/081685 patent/WO2008049027A1/en not_active Ceased
- 2007-10-17 CN CN2007800387031A patent/CN101611016B/zh not_active Expired - Fee Related
- 2007-10-17 KR KR1020097009986A patent/KR101419965B1/ko not_active Expired - Fee Related
- 2007-10-17 MX MX2009004096A patent/MX2009004096A/es active IP Right Grant
- 2007-10-17 JP JP2009533511A patent/JP5343267B2/ja not_active Expired - Fee Related
- 2007-10-17 CA CA2667053A patent/CA2667053C/en not_active Expired - Fee Related
- 2007-10-17 US US12/311,862 patent/US8188124B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 US US13/476,216 patent/US8399495B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2667053A1 (en) | 2008-04-24 |
| US8399495B2 (en) | 2013-03-19 |
| AU2007311026B2 (en) | 2012-05-17 |
| EP2114895A4 (en) | 2011-06-22 |
| US20120283204A1 (en) | 2012-11-08 |
| KR101419965B1 (ko) | 2014-07-16 |
| KR20090068286A (ko) | 2009-06-25 |
| EP2114895A1 (en) | 2009-11-11 |
| MX2009004096A (es) | 2009-06-16 |
| JP2010506953A (ja) | 2010-03-04 |
| US20100292284A1 (en) | 2010-11-18 |
| BRPI0718310A2 (pt) | 2013-11-19 |
| AU2007311026A1 (en) | 2008-04-24 |
| US8188124B2 (en) | 2012-05-29 |
| CN101611016A (zh) | 2009-12-23 |
| CA2667053C (en) | 2015-04-28 |
| WO2008049027A1 (en) | 2008-04-24 |
| CN101611016B (zh) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5343267B2 (ja) | タラロゾール代謝物 | |
| US11827605B2 (en) | Isoquinoline compounds and their use in treating AhR imbalance | |
| US9944632B2 (en) | Compounds having estrogen receptor alpha degradation activity and uses thereof | |
| CN112979743A (zh) | 白桦脂酸衍生物及其应用 | |
| CN116194449B (zh) | 一种内皮素a(eta)受体拮抗剂化合物及其制备方法和医药用途 | |
| EP2987784A1 (de) | Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln | |
| EP4520752A1 (en) | Carebastine salt and use thereof | |
| US6638970B2 (en) | Substituted alkylene diamine compounds | |
| EP4183785A1 (en) | Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof | |
| WO2015092720A1 (en) | Metabolites of sonidegib (lde225) | |
| EP1286672B1 (en) | S-methyl-dihydro-ziprasidone for the treatment of ocular disorders. | |
| KR102457316B1 (ko) | 새로운 5형포스포디에스테라아제 억제제 및 그 용도 | |
| US20020132797A1 (en) | DNA-cleaving antitumor agents | |
| RU2481335C2 (ru) | Производные дигидроимидазола, замещенного конденсированным карбоциклом, используемые для снятия боли и лечения состояний, подобных глаукоме | |
| WO2001070217A1 (en) | Dna-cleaving antitumor agents | |
| JPS61180788A (ja) | チオピラノピリミジン誘導体およびその酸付加塩 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100727 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100727 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130625 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130718 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130724 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130718 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |